Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

Home
/
update
/
details

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

NextEdge Admin

19 Nov 2024

2 min 18 sec

BioScience,Genomics,digital PCR,Next-Generation Sequencing

Stilla Technologies, a global leader in digital PCR (dPCR) solutions, has partnered with Source BioScience, a premier UK-based genomics service provider, to bring state-of-the-art dPCR technology to the UK and Ireland. Through this collaboration, Source BioScience will become the first in the region to offer Stilla’s innovative NIO system, revolutionizing molecular genetics research.

This partnership leverages Source BioScience’s robust infrastructure and expertise in molecular genetics and Next-Generation Sequencing (NGS). By combining their strengths, the organizations aim to provide enhanced solutions for biopharma viral vector work, bolstering support for the biopharma and clinical research communities.

Alex Widger, UK/Ireland Country Manager at Stilla Technologies, shared his enthusiasm: “I am thrilled that Source BioScience will have the first NIO system in the UK and Ireland, extending the reach of our dPCR innovation to diverse customer segments.”

Richard Stevens, Director of Genomics at Source BioScience, emphasized the significance of the partnership: “Adding digital PCR to our service portfolio allows us to meet the evolving needs of life science researchers. Partnering with Stilla Technologies ensures we offer cutting-edge dPCR tools to the research community.”

The collaboration also strengthens Stilla’s work with Niba Labs, further supporting advancements in vector research. With the NIO system, researchers will gain access to precise genomic analysis, accelerating progress in molecular diagnostics and gene therapy. This partnership marks a significant milestone in bringing advanced genomics solutions to the UK market.